<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="152856">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01655290</url>
  </required_header>
  <id_info>
    <org_study_id>GAD-1140-WIL-0020-I</org_study_id>
    <nct_id>NCT01655290</nct_id>
  </id_info>
  <brief_title>Comparison of Gadobutrol and Gadobenate Dimeglumin for Delayed Enhancement Cardiac MRI</brief_title>
  <acronym>Gadovit</acronym>
  <official_title>Intraindividual Comparison of the Diagnostic Accuracy Using Gadobutrol (Gadovist®) Versus Gadobenat Dimeglumin (Multihance®) for Delayed Enhancement MRI of Myocardial Infarction.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität München</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Technische Universität München</source>
  <oversight_info>
    <authority>Germany: District Government of Upper Bavaria</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims at evaluating the diagnostic efficacy of Gadobutrol versus Gadobenate
      dimeglumine at similar dose of 0.1mmol/kg for assessment of myocardial infarction by delayed
      enhancement cardiac Magnetic Resonance Imaging
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">May 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Efficacy (contrast-to-noise ratio)</measure>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Subacute/Chronic Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Gadobutrol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>first session gadobutrol second session gadobenate dimeglumin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Demeglumin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>first session gadobenate dimeglumin second session gadobutrol</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Gadovist® (Gadobutrol), Multihance® (Gadobenate dimeglumin)</intervention_name>
    <description>Other (Diagnostic)</description>
    <arm_group_label>Gadobutrol</arm_group_label>
    <arm_group_label>Demeglumin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of myocardial infarction

          -  Age ≥ 18 years and ≤ 80 years

          -  Informed consent

          -  Male patients as well as female patients using contraceptives

        Exclusion Criteria:

          -  Patients with a heart pacemaker, with magnetic material or other magnetic implants.

          -  Renal failure (GFR &lt;30ml/min)

          -  Patients with known allergy to a Gadolinium-containing contrast agent

          -  Drugs or alcohol addiction, dementia
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Institut für Radiologie - Klinikum Rechts der Isar</name>
      <address>
        <city>Munic</city>
        <state>Bavaria</state>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>May 15, 2013</lastchanged_date>
  <firstreceived_date>July 30, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
